Potential prognostic value of miRNAs as biomarker for progression and recurrence after nephrectomy in renal cell carcinoma: a literature review
Author:
Fasanella Daniela1, Antonaci Alessio1ORCID, Esperto Francesco2, Scarpa Roberto M.2, Ferro Matteo3, Schips Luigi1, Marchioni Michele1
Affiliation:
1. Department of Medical , Oral and Biotechnological Sciences, G. d’Annunzio University of Chieti, Urology Unit, SS Annunziata Hospital , Chieti , Italy 2. Department of Urology , Campus Biomedico University of Rome , Rome , Italy 3. Division of Urology , European Institute of Oncology-IRCCS , Milan , Italy
Abstract
Abstract
Objectives
We provide a systematic literature review on tissue miRNAs in patients with RCC to evaluate and summarize their usefulness as prognostic markers. We undertook a systematic search for articles in English using the PubMed-Medline database from January 2010 to December 2020. Studies were identified and selected according to the PRISMA criteria and the PICO methodology. The population consisted of RCC patients undergoing nephrectomy and the main outcome of interest was recurrence-free survival (RFS). Only studies providing hazard ratios (HRs) from multivariate or univariate analyzes with corresponding 95% confidence intervals (CI) and/or area under the curve (AUC) were considered.
Content
All nine included studies (1,541 patients) analyzed the relationship between tissue miRNA expression levels (up or downregulated) and RFS. Some of these found that the methylation status of miR-9-1, miR-9-3 and miR-124 was associated with a high risk of relapse. Moreover, miR-200b overexpression was associated with OS. MiR-210 overexpression indicated a shorter OS than those who were miR-210 negative. Finally, patients with high miR-125b expression had shorter CSS than those with low expression; similarly, patients with low miR-126 expression also had shorter CSS time.
Summary and Outlook
Several studies tested the usefulness of specific miRNAs to predict RCC recurrence. Some of them showed a fair accuracy and strong relationship between specific miRNA over or under-expression and survival outcomes. However, results from these studies are preliminary and miRNAs use in routine clinical practice is still far to come.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,Public Health, Environmental and Occupational Health,Health Policy,Medicine (miscellaneous)
Reference45 articles.
1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2020. CA A Cancer J Clin 2020;70:7–30. https://doi.org/10.3322/caac.21590. 2. Dabestani, S, Marconi, L, Kuusk, T, Bex, A. Follow-up after curative treatment of localised renal cell carcinoma. World J Urol 2018;36:1953–9. https://doi.org/10.1007/s00345-018-2338-z. 3. Wang, G, Chen, L, Meng, J, Chen, M, Zhuang, L, Zhang, L. Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma. Int Urol Nephrol 2013;45:373–9. https://doi.org/10.1007/s11255-012-0374-y. 4. Ljungberg, B, Bensalah, K, Canfield, S, Dabestani, S, Hofmann, F, Hora, M, et al.. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913–24. https://doi.org/10.1016/j.eururo.2015.01.005. 5. Marchioni, M, Martel, T, Bandini, M, Pompe, RS, Tian, Z, Kapoor, A, et al.. Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1–2 N0 M0 renal cell carcinoma. World J Urol 2017;35:1899–905. https://doi.org/10.1007/s00345-017-2082-9.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|